Boston Scientific’s Dual-Drug Stent Strategy Yields 50% Market Share In Q1
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific achieved a 50% share of the U.S. drug-eluting stent market in the first quarter on the strength of its Taxus and Promus systems - up three points from the final quarter of 2008, according to the company